Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.60 USD
Change Today -0.0403 / -2.46%
Volume 134.6K
TBIO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

transgenomic inc (TBIO) Snapshot

Open
$1.70
Previous Close
$1.64
Day High
$1.70
Day Low
$1.55
52 Week High
04/25/14 - $4.50
52 Week Low
03/26/15 - $1.23
Market Cap
19.0M
Average Volume 10 Days
57.1K
EPS TTM
$-2.35
Shares Outstanding
11.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRANSGENOMIC INC (TBIO)

Related News

No related news articles were found.

transgenomic inc (TBIO) Related Businessweek News

No Related Businessweek News Found

transgenomic inc (TBIO) Details

Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States and internationally. It operates in two segments, Laboratory Services, and Genetic Assays and Platforms. The Laboratory Services segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders, and oncology. This segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. In addition, it employs various genomic testing service technologies, including ICE COLD-PCR technology, a proprietary platform technology that enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA, and circulating tumor cells. The Genetic Assays and Platforms segment offers the WAVE System, which has applicability to genetic variation detection in molecular genetic research and molecular diagnostics. It also manufactures and sells consumable products, including a range of chromatography columns, which can be used on multiple and independent platforms. The company sells its products through direct sales, support staff, dealers, and distributors to pharmaceutical, biotech, and commercial companies, as well as academic and medical institutions. Transgenomic, Inc. has a collaboration agreement with PDI, Inc. The company was founded in 1997 and is headquartered in Omaha, Nebraska.

transgenomic inc (TBIO) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $87.5K
Compensation as of Fiscal Year 2013.

transgenomic inc (TBIO) Key Developments

Transgenomic Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Transgenomic Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company's net sales were $7.7 million compared with $6.2 million for the same period in 2013, an increase of 24%. The net loss was $5.8 million, or $0.77 per share, compared with a net loss of $4.0 million or $0.57 per share for the fourth quarter of 2013. Loss from operations were $5.8 million against $3.6 million for the same period a year ago. Loss before income taxes was $5.7 million compared to $4.1 million for the same period a year ago. MODIFIED LBITDA was $5.2 million against $2.7 million for the same period a year ago. For the year, net sales were $27.0 million, compared with $27.5 million for the same period in 2013. The $0.5 million decline includes a 13% decrease in the Genetic Assays and Platforms segment as a result of lower instrument sales and lower bioconsumables sales resulting from the sale of the company's Surveyor Kits product line during 2014. Net loss was $13.9 million or $2.01 per share, compared with a net loss of $16.0 million, or $2.30 per share, for the comparable period of 2013. Loss from operations were $17.3 million against $15.8 million for the same period a year ago. Loss before income taxes was $13.4 million compared to $16.0 million for the same period a year ago. MODIFIED LBITDA was $10.0 million against $12.5 million for the same period a year ago.

Transgenomic Inc. to Report Q4, 2014 Results on Apr 15, 2015

Transgenomic Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Daylight on Apr 15, 2015

Transgenomic Inc., Q4 2014 Earnings Call, Apr 15, 2015

Transgenomic Inc., Q4 2014 Earnings Call, Apr 15, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBIO:US $1.60 USD -0.0403

TBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Illumina Inc $191.16 USD -1.86
Laboratory Corp of America Holdings $124.41 USD -1.08
QIAGEN NV €23.06 EUR -0.57
Quest Diagnostics Inc $75.33 USD -0.82
Sequenom Inc $4.28 USD -0.06
View Industry Companies
 

Industry Analysis

TBIO

Industry Average

Valuation TBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENOMIC INC, please visit www.transgenomic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.